duloxetine hydrochloride has been researched along with Cancer Pain in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 7 (63.64) | 2.80 |
| Authors | Studies |
|---|---|
| Agar, M; Allcroft, P; Ariyoshi, K; Brown, L; Clark, K; Currow, DC; Fazekas, B; Fujiwara, N; Hasuo, H; Ishiki, H; Iwase, S; Kochovska, S; Koyama, A; Le, B; Lee, J; Lovell, M; Matsuda, Y; Matsuoka, H; Miyaji, T; Oyamada, S; Phillips, J; Satomi, E; Yamaguchi, T | 1 |
| McGinn, R; Smith, MA; Zerfas, I | 1 |
| Ariyoshi, K; Hasegawa, Y; Hasuo, H; Ishiki, H; Iwase, S; Kataoka, Y; Kawaguchi, T; Koyama, A; Matsuda, Y; Matsumoto, Y; Matsuoka, H; Miyaji, T; Morita, T; Nakura, M; Ohtake, Y; Otani, H; Otsuka, M; Oyamada, S; Sakai, K; Sakuma, H; Satomi, E; Tahara, K; Tokoro, A; Tsukuura, H; Yamaguchi, T | 1 |
| Gül, HL; Gül, ŞK; Tepetam, H | 1 |
| Hao, H; Ichimaru, Y; Ijichi, H; Ishii, Y; Kajiwara, I; Kim, J; Kitajima, O; Masamune, A; Oshima, Y; Sano, M; Suzuki, T | 1 |
| Corradini, L; Imam, MZ; Kuo, A; Nicholson, JR; Smith, MT | 1 |
| Abdullaziz, S; Curry, ZA; Dang, MC; Del Fabbro, EG; Sima, AP | 1 |
| Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T | 1 |
| Marchant, J | 1 |
| Ariyoshi, K; Inoue, A; Kizawa, Y; Koyama, A; Matsuoka, H; Oyamada, S; Tagami, K | 1 |
| Ariyoshi, K; Hasegawa, Y; Hasuo, H; Ishiki, H; Iwase, S; Kataoka, Y; Kawaguchi, T; Koyama, A; Matsuda, Y; Matsumoto, Y; Matsuoka, H; Miyaji, T; Morita, T; Ohtake, Y; Otani, H; Otsuka, M; Oyamada, S; Sakai, K; Sakuma, H; Satomi, E; Shinomiya, T; Tokoro, A; Tsukuura, H; Yamaguchi, T | 1 |
1 review(s) available for duloxetine hydrochloride and Cancer Pain
| Article | Year |
|---|---|
Pharmacologic Management of Cancer-Related Pain in Pregnant Patients.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Duloxetine Hydrochloride; Female; Gabapentin; Humans; Neoplasms; Neuralgia; Nociceptive Pain; Pregnancy | 2023 |
5 trial(s) available for duloxetine hydrochloride and Cancer Pain
| Article | Year |
|---|---|
Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol.
Topics: Adult; Analgesics, Opioid; Cancer Pain; Clinical Trials, Phase III as Topic; Double-Blind Method; Duloxetine Hydrochloride; Humans; Multicenter Studies as Topic; Neoplasms; Neuralgia; Pregabalin; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial-JORTC-PAL08 (DIRECT) study.
Topics: Adult; Aged; Cancer Pain; Chronic Pain; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Neoplasms; Neuralgia; Pain Measurement; Placebos; Prognosis; Treatment Outcome | 2020 |
Duloxetine and pregabalin in neuropathic pain of lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Cancer Pain; Duloxetine Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neuralgia; Pain Measurement; Pregabalin; Prospective Studies; Quality of Life; Treatment Outcome | 2020 |
Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cancer Pain; Cyclohexanecarboxylic Acids; Double-Blind Method; Duloxetine Hydrochloride; Gabapentin; gamma-Aminobutyric Acid; Humans; Middle Aged; Neoplasms; Neuralgia; Research Design; Young Adult | 2017 |
Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08).
Topics: Aged; Analgesics, Opioid; Cancer Pain; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Neuralgia; Pain Measurement; Pregabalin; Treatment Outcome | 2019 |
5 other study(ies) available for duloxetine hydrochloride and Cancer Pain
| Article | Year |
|---|---|
Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects.
Topics: Animals; Cancer Pain; Duloxetine Hydrochloride; Humans; Mice; Norepinephrine; Pancreatic Neoplasms; Quality of Life | 2020 |
Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain.
Topics: Analgesics; Animals; Bone and Bones; Cancer Pain; Disease Models, Animal; Duloxetine Hydrochloride; Glycine Plasma Membrane Transport Proteins; Hyperalgesia; Male; Neuralgia; Pain Measurement; Pain Threshold; Pregabalin; Prostatic Neoplasms; Rats; Rats, Wistar | 2020 |
Combination therapy with methadone and duloxetine for cancer-related pain: a retrospective study.
Topics: Cancer Pain; Duloxetine Hydrochloride; Humans; Methadone; Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Acupuncture in cancer study reignites debate about controversial technique.
Topics: Acupuncture; Antidepressive Agents; Aromatase Inhibitors; Breast Neoplasms; Cancer Pain; Duloxetine Hydrochloride; Female; Humans; Medication Adherence; Placebo Effect; Reproducibility of Results | 2017 |
Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: a nationwide cross-sectional survey.
Topics: Adjuvants, Pharmaceutic; Adult; Analgesics; Analgesics, Opioid; Attitude of Health Personnel; Cancer Pain; Cross-Sectional Studies; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Neuralgia; Palliative Care; Physicians; Pregabalin; Specialization; Surveys and Questionnaires | 2019 |